Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)

European Journal of Cancer

Volumn 37, Issue SUPPL. 1, 2001, Pages 11-17

  Van de Vijver, M J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; erbB 2; HER2; Trastuzumab

Indexed keywords

GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN ANALYSIS; STANDARDIZATION;

EID: 0035126401     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(00)00403-2     Document Type: Article

References (64)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. The biology of erbB-2/neu/HER-2 and its role in cancer
3. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
4. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
5. Regulation of signal transduction and signal diversity by receptor oligomerization
6. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification
9. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
10. Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor
11. HER2 causes transformation and tumorigenesis of NIH 3T3 cells
12. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
13. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
14. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
15. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma and limited prognostic value in stage II breast cancer
16. Biophenotypes of breast carcinoma in-situ defined by image analysis of biological parameters
17. Ductal carcinoma in-situ: Assessment of necrosis in nuclear morphology and their association with biological markers
18. Immunophenotype of intraductal carcinoma
19. Prognostic variables in invasive breast cancer: Contribution of comedo versus noncomedo in situ component
20. Differential distribution of erbB-2 and pS2 proteins in ductal carcinoma in-situ of the breast
21. Immunohistochemical evaluation of c-erb-B2 oncogene expression in ductal carcinoma in situ an atypical ductal hyperplasia of the breast
22. Ductal carcinoma in-situ of the breast: Correlation between histologic classification and biologic markers
23. Mammographically-detected ductal in-situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: Correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity
24. Overexpression of the c-erbB-2 oncogene: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance
25. Correlation of c-erbB2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
26. Amplification of the c-erb B-2 oncogene in prognosis of breast adenocarcinoma
27. Prognostic importance of c-erbB-2 expression in breast cancer
28. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer
29. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in breast cancer
30. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors
31. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
32. Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up
33. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
34. Long-term survival in breast cancer related to overexpression in the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11
35. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
36. HER-2/neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease
37. Prognostic significance of c-erbB-2 expression in node negative breast cancer
38. Follow-up study of HER-2/neu amplification in primary breast cancer
39. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
40. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
41. Expression of epidermal growth factor receptor and c-erb B2 during the development of tamoxifen resistance in human breast cancer
42. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
43. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and tamoxifen efficacy
44. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
45. Lack of interaction of tamoxifen (T) use and ErbB-2/HER-2/neu (H) expression in CALGB 8541: A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouracil (CAF) in node-positive primary breast cancer (BC)
46. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
47. c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
48. Benefit of CMF treatment in lymph-node positive breast cancer overexpressing HER2
49. Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil
50. Dose and dose-intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B
51. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
52. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
53. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
54. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications
55. Quantitation of c-erbB-2 gene amplification in breast cancer tissue by competitive PCR
56. The c-erbB-2 oncogene amplification by competitive PCR in aneuploid cell clones sorted from breast cancer samples
57. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
58. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects
59. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells
60. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
61. The HercepTest assay: Another perspective
62. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
63. Immunohistochemical assays for HER2 overexpression
64. Increased HER2 with U.S. Food and Drug Administration-approved antibody